ART Doesn’t Increase Hormone Receptor-Positive Breast Cancer Recurrence Risk
Dec 7, 2023
Dr. Hatem Azim explains his new analysis of data from the POSITIVE trial.
At the 2023 San Antonio Breast Cancer Symposium, Dr. Hatem Azim presented a new analysis of information from the POSITIVE trial, which found that younger women diagnosed with early-stage, hormone receptor-positive breast cancer could safely pause hormonal therapy to try to become pregnant. His new analysis looked at whether the women could use fertility preservation and assisted reproductive technologies (ART) without increasing the risk of the cancer coming back (recurrence).
Listen to the podcast to hear Dr. Azim discuss:
- the types of fertility preservation and ART used
- which techniques were the most successful
- the results of his analysis